ASLAN Pharmaceuticals Limited American Depositary Shares - ASLN STOCK NEWS

ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced that it received a delisting determination from Nasdaq on July 9, 2024, due to non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements. The company's board has decided not to appeal this decision. ASLAN had previously been notified of these compliance issues and was given time to address them. On July 3, 2024, the company implemented a ratio change for its American Depositary Shares (ADSs), resulting in a closing price above $1.00. However, as of the press release date, the bid price had only closed above $1.00 for five consecutive business days, falling short of the required ten to twenty-day compliance period.

ASLAN Pharmaceuticals has announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares. Effective July 3, 2024, the ratio will shift from 1 ADS representing 25 ordinary shares to 1 ADS representing 200 ordinary shares. This will effectively result in a one-for-eight reverse ADS split. Existing ADS holders do not need to take action, as the change will occur automatically. The trading price of ADSs is expected to increase proportionally, but there is no guarantee it will be eight times the pre-change price. The ADSs will continue trading under the symbol 'ASLN' on Nasdaq.

ASLAN Pharmaceuticals presented late-breaking translational data on eblasakimab at the American Thoracic Society International Conference. The study, comparing eblasakimab to dupilumab in human tissue models of COPD, showed that eblasakimab significantly improved airway function and bronchodilation.

Eblasakimab effectively blocked Type-2 inflammation in lung tissue, outperforming dupilumab in reducing airway constriction and enhancing dilation. The findings suggest eblasakimab as a promising therapeutic option for COPD and other Type-2 driven lung conditions.

ASLAN Pharmaceuticals reported positive interim data from the TREK-DX study of eblasakimab, showing unprecedented efficacy in atopic dermatitis patients. Additionally, the company announced favorable patent opinions and collaborations with Zenyaku. Financially, ASLAN saw a decrease in cash used for operations and research expenses, resulting in a lower net loss for Q1 2024.

ASLAN Pharmaceuticals will present new positive data from an interim analysis of the Phase 2 TREK-DX study of Eblasakimab in dupilumab-experienced atopic dermatitis patients during a virtual KOL event. The data support the effectiveness of Eblasakimab in patients with an inadequate response to dupilumab, showing significant improvements in EASI and vIGA scores. The presentation will include secondary endpoints, rapid onset of effect, low discontinuation rates, and promising outcomes for patients with prior inadequate response to dupilumab. The event will feature discussions with key opinion leaders on the emerging market for alternative treatments in AD patients.

ASLAN Pharmaceuticals has announced an expanded research collaboration with Zenyaku to investigate the differentiation of eblasakimab versus other biologics for atopic dermatitis. The partnership will deepen the understanding of why some patients respond better to eblasakimab over dupilumab. The new agreement builds on their existing commercial partnership in Japan. The research aims to explore the receptor biology and kinetics to understand eblasakimab's unique mechanism of action.

ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company, will host a virtual Key Opinion Leader (KOL) Event discussing treatment options for atopic dermatitis patients with an inadequate response to Dupilumab on May 7, 2024. The event will feature leading medical professionals and present new data from the interim analysis of the TREK-DX study, showcasing positive results for Eblasakimab, a potential first-in-class biologic candidate.

ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease (COPD) has been accepted for presentation at the American Thoracic Society International Conference 2024. The poster will discuss how Eblasakimab alleviates bronchial airway constriction in COPD patients. The presentation will be made by Dr. Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.

ASLAN Pharmaceuticals announces positive interim results from the Phase 2 study of Eblasakimab in Dupilumab-experienced Atopic Dermatitis patients. The study shows unprecedented efficacy data with significant improvements in EASI scores, vIGA scores, and itch relief compared to placebo. Eblasakimab demonstrated high effectiveness in patients previously treated with dupilumab, indicating its potential as a new therapy for this patient population.